EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity

Hanne Due iD, Asta Brogaard iD, Issa Ismail Issa iD, Maja Zimmer Jakobsen iD, Cathrine Sylvester iD, Anne Krogh Nøhr, Louiza Bohn Thomsen, Martin Kristian Thomsen iD, Rasmus Froberg Brøndum iD, Karen Dybkær iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hanne Due und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Bortezomib, Cell Cycle Proteins, Nuclear Proteins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Cancer Society, A.P Moeller Foundation, The Danish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Numerous clinical trials have attempted to improve first-line R-CHOP treatment of diffuse large B-cell lymphoma (DLBCL) through the addition or substitution of drugs. The REMoDL-B trial, testing the addition of bortezomib (RB-CHOP), revealed that ABC and molecular high-grade DLBCL patients benefit from bortezomib. The aim of this study was to achieve a better understanding of the bortezomib response in DLBCL through a functional investigation of clinically identified markers. A retrospective analysis of transcriptional and clinical data from the REMoDL-B trial was conducted to identify genes associated with bortezomib response, identifying CDCA2. DLBCL patients with high expression of CDCA2 had a superior survival outcome when treated with RB-CHOP in comparison to R-CHOP, whereas no difference in outcome was observed for patients with low CDCA2. Moreover, CDCA2 was found to be overexpressed in DLBCL compared to non-malignant tissue, and to have higher levels in GCB and MYC/BCL2 double-expressor patients. Functional in vitro and in vivo studies revealed that knockout of CDCA2 decreased DLBCL cell proliferation and a bortezomib dose–response analysis showed less sensitivity in CDCA2 knockout cells compared to control cells. This study shows that DLBCL patients with high CDCA2 expression benefitted from the addition of bortezomib to R-CHOP and functional studies documented a direct impact of CDCA2 on the bortezomib response in DLBCL cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseBortezomibCell Cycle ProteinsNuclear ProteinsHumansCell ProliferationCell Line, TumorGene Expression Regulation, NeoplasticPrednisoneAnimalsAntineoplastic Combined Chemotherapy ProtocolsVincristineRituximabFemaleDoxorubicinMaleCyclophosphamideDrug Resistance, NeoplasmMiceMiddle AgedRetrospective StudiesAntineoplastic AgentsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CDCA2CRISPRDLBCLRB-CHOPbortezomibdiffuse large B-cell lymphomatreatment response

Substanzen

BortezomibCell Cycle ProteinsPrednisoneVincristineRituximabDoxorubicinNuclear ProteinsCyclophosphamideAntineoplastic AgentsR-CHOP protocol

Autor:innen und Institutionen

  • Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, 9260 Gistrup, Denmark.
  • Center for Clinical Data Science, Aalborg University Hospital, and Aalborg University, 9260 Gistrup, Denmark.
  • Department of Health Science and Technology, Aalborg University, 9260 Gistrup, Denmark.
  • Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.

ORCID-Profile: Hanne Due, Asta Brogaard, Issa Ismail Issa, Maja Zimmer Jakobsen, Cathrine Sylvester, Martin Kristian Thomsen, Rasmus Froberg Brøndum, Karen Dybkær

Förderung

  • Danish Cancer Society
  • A.P Moeller Foundation
  • The Danish Cancer Society
  • A.P. Moeller Foundation

Zitieren

APA

Due, H., Brogaard, A., Issa, I. I., Jakobsen, M. Z., Sylvester, C., Nøhr, A. K., Thomsen, L. B., Thomsen, M. K., Brøndum, R. F., & Dybkær, K. (2025). Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125596

Vancouver

Due H, Brogaard A, Issa II, Jakobsen MZ, Sylvester C, Nøhr AK, et al. Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125596

BibTeX
@article{Due2025,
  author = {Due, Hanne and Brogaard, Asta and Issa, Issa Ismail and Jakobsen, Maja Zimmer and Sylvester, Cathrine and Nøhr, Anne Krogh and Thomsen, Louiza Bohn and Thomsen, Martin Kristian and Brøndum, Rasmus Froberg and Dybkær, Karen},
  title = {Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125596}
}
Kostenlos starten →